CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 14 enrolled
Drug / intervention
Donepezil hydrochloridedrug
Likely dose
Donepezil hydrochloride 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00477659
NCT00477659Phase 4Completed
CompareCT.gov

A Single Center Study To Examine Neural Correlates Of Cognition In Subjects With Mild Alzheimer's Disease After Three Months Of Open Label Donepezil HCl (Aricept® ) Treatment

Eisai Inc.·interventional·Posted May 24, 2007·Updated Nov 10, 2021

In Brief

A Phase 4 clinical trial evaluating Donepezil hydrochloride for Alzheimer's Disease. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion; in the Medial Temporal Lobe (MTL) network in subjects in the early stage of Alzheimer's Disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 24, 2007
Enrollment StartJul 23, 2007
Primary CompletionAug 15, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.1 years ago

Interventions

Donepezil hydrochloridedrug

Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks